RogCon founders from left to right: Kelley Dalby, Dr. Steven Petrou and Alex Nemiroff.
RogCon is a biotechnology company focused on discovering and developing novel therapeutics for children suffering from SCN2A mutations, where no solutions currently exist. The Company was founded by two parents of children affected by SCN2A mutations, Alex Nemiroff (CEO) and Kelley Dalby (SVP), and Dr. Steven Petrou (CSO), a renowned neuroscientist specializing in genetic epilepsy.
Underwhelmed at the current standard of care and grim prognosis, the Founders set out to amass the world’s leading experts in epilepsy research and drug development to support and advance the Company’s efforts to identify and bring to market new disease-modifying ways to treat SCN2A disease. This led to partnerships with key biopharma and academic institutions, including a collaboration with Ionis Pharmaceuticals, Inc. [Nasdaq: IONS] to harness their expertise in antisense oligonucleotide drug discovery.
Today, the RogCon team consists of dedicated scientists, researchers and professionals, advancing several new treatments to market and all guided by the singular goal of changing the lives of children and families impacted by mutations in SCN2A.
Our co-founder, Dr. Steven Petrou, leads The Florey Institute of Neuroscience and Mental Health, one of the largest and most highly respected brain research centers, and the leading institute in the world for genetic epilepsy research.
Connor was born and labeled healthy, and we were sent home from the hospital. We were so excited that we were able to give our older son Chase a brother and a best friend for life. But it was short-lived. A few weeks after birth, he cried often, rarely slept and had a lot of gastrointestinal issues and feeding difficulties. At this point I naively thought that when a person was ill, he went to the doctor, received a diagnosis, took a medication and got better. I thought diseases were cured and people recovered. I was in for the shock of my life having Connor as my son.